Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

947 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Clinical evaluation of a multitarget fecal immunochemical test-sDNA test for colorectal cancer screening in a high-risk population: a prospective, multicenter clinical study.
Hu YT, Chen XF, Zhai CB, Yu XT, Liu G, Xiong ZG, Wang ZQ, Cai SJ, Li WC, Kong XX, Xiao Q, Wang CH, Tao ZH, Niu LY, Men JL, Wang Q, Wei SZ, Hu JJ, Yang TH, Peng JJ, Jiang GZ, Lv N, Chen YY, Zheng S, Gu YH, Ding KF. Hu YT, et al. Among authors: chen yy, chen xf. MedComm (2020). 2023 Aug 12;4(4):e345. doi: 10.1002/mco2.345. eCollection 2023 Aug. MedComm (2020). 2023. PMID: 37576863 Free PMC article.
Low-dose apatinib combined with camrelizumab and the SOX regimen in the neoadjuvant treatment of locally advanced gastric/gastroesophageal junction adenocarcinoma (SPACE-neo): a protocol for an open-label, single-arm, clinical trial.
Pan L, Tian Y, Wang K, Tang J, Liu J, Zhang J, Wang M, Liu J, Xu H, Chen X. Pan L, et al. J Gastrointest Oncol. 2022 Dec;13(6):3300-3313. doi: 10.21037/jgo-22-1158. J Gastrointest Oncol. 2022. PMID: 36636043 Free PMC article.
Efficacy and safety of XELOX combined with anlotinib and penpulimab vs XELOX as an adjuvant therapy for ctDNA-positive gastric and gastroesophageal junction adenocarcinoma: a protocol for a randomized, controlled, multicenter phase II clinical trial (EXPLORING study).
Chen Y, Zhang J, Han G, Tang J, Guo F, Li W, Xie L, Xu H, Zhang X, Tian Y, Pan L, Shu Y, Ma L, Chen X. Chen Y, et al. Front Immunol. 2023 Oct 31;14:1232858. doi: 10.3389/fimmu.2023.1232858. eCollection 2023. Front Immunol. 2023. PMID: 38022553 Free PMC article.
First-line camrelizumab (a PD-1 inhibitor) plus apatinib (an VEGFR-2 inhibitor) and chemotherapy for advanced gastric cancer (SPACE): a phase 1 study.
Chen X, Xu H, Chen X, Xu T, Tian Y, Wang D, Guo F, Wang K, Jin G, Li X, Wang R, Li F, Ding Y, Tang J, Fang Y, Zhao J, Liu L, Ma L, Meng L, Hou Z, Zheng R, Liu Y, Guan N, Zhang B, Tong S, Chen S, Li X, Shu Y. Chen X, et al. Signal Transduct Target Ther. 2024 Mar 25;9(1):73. doi: 10.1038/s41392-024-01773-9. Signal Transduct Target Ther. 2024. PMID: 38528050 Free PMC article. Clinical Trial.
947 results